CTOs on the Move

Frequency Therapeutics

www.frequencytx.com

 
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Dan O'Neill
Vice President of Information Technology Profile
Jeff Hrkach
Senior Vice President of Technology Development Profile

Funding

Frequency Therapeutics raised $32M on 04/17/2017
Frequency Therapeutics raised $60M on 01/07/2019
Frequency Therapeutics raised $62M on 07/23/2019
Frequency Therapeutics raised $42.3M on 07/17/2020

Similar Companies

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences` mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Ymmunobio

At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on unique and first-in-class targets while selecting the optimal approach to dev...

ACGT DNA Technologies

ACGT DNA Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.